Issue 1-2/2013

  • IMI: Stem cells at centre-stage

    In this issue:

    Big Pharma is for the first time directly addressing the need for better disease models than those available through animal experimentation. With a €50m EU project led by Hoffmann-la Roche and the University of Oxford, the Innovative Medicines Initiative's StemBaNCC project is using stem cells to establish 1,500 human cell lines to mimic disease processes in the bodies of the ill. One of the project's goals is to lower the extremely high failure rate in screening and early clinical testing of drug candidates.

    Volume 2015

    Volume 2014

    Volume 2013

    Volume 2012

    © 2007-2015 BIOCOM


    Alle Kurse


    • PROTHENA PLC (IE)68.70 USD9.45%
    • HYBRIGENICS (F)1.63 EUR9.40%
    • PHARMING (NL)0.34 EUR6.25%


    • SERODUS (N)2.60 NOK-15.58%
    • ZELTIA (E)3.69 EUR-8.44%
    • IXICO (UK)33.00 GBP-7.04%


    • DBV TECHNOLOGIES (F)77.15 EUR48.4%
    • IXICO (UK)33.00 GBP46.7%
    • ADOCIA (F)90.05 EUR40.7%


    • BIOTEST (D)25.67 EUR-63.3%
    • CHRONTECH PHARMA (S)0.01 SEK-50.0%
    • BIOTECH PHARMACON (N)9.35 NOK-46.0%


    • ADOCIA (F)90.05 EUR543.7%
    • FORMYCON (D)27.30 EUR298.5%
    • PROTHENA PLC (IE)68.70 USD295.5%


    • CHRONTECH PHARMA (S)0.01 SEK-88.9%
    • NEOVACS (F)1.05 EUR-70.1%
    • BIOTEST (D)25.67 EUR-68.7%

    No liability assumed, Date: 28.07.2015